Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success
Current Oncology Reports · 2024
DOI: 10.1007/s11912-024-01544-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology Reports, 2024. Verfasst von Mike Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Protein Kinase Inhibitors, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
PURPOSE OF REVIEW: This report highlights several of the recent therapeutic advancements in the treatment of BRAF-mutant tumors, discusses the most common adverse events observed with BRAF-targeted agents, and suggests strategies to manage and mitigate treatment-related toxicities. RECENT FINDINGS: BRAF and MEK inhibitors represent a significant advancement in the treatment of BRAF-mutated malignancies with data across tumor types demonstrating the anti-tumor efficacy of dual MAPK inhibition. Although these agents have a reasonable toxicity profile, variable side effects across organ systems can develop. The discovery of activating BRAF mutations and subsequent development of BRAF and MEK inhibitors has transformed the treatment algorithms of BRAF-mutant malignancies. With increased application of these targeted regimens, identification and prompt management of their unique adverse events are crucial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA.
- Harvard Medical School, Boston, MA, USA.
- Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
- Division of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA. mmooradian@mgh.harvard.edu.
- Harvard Medical School, Boston, MA, USA. mmooradian@mgh.harvard.edu.
Zitieren
APA
Wang, M., Sullivan, R. J., & Mooradian, M. J. (2024). Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success. Current Oncology Reports. https://doi.org/10.1007/s11912-024-01544-3
Vancouver
Wang M, Sullivan RJ, Mooradian MJ. Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success. Current Oncology Reports. 2024. doi:10.1007/s11912-024-01544-3
BibTeX
@article{Wang2024,
author = {Wang, Mike and Sullivan, Ryan J and Mooradian, Meghan J},
title = {Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success},
journal = {Current Oncology Reports},
year = {2024},
doi = {10.1007/s11912-024-01544-3}
}
EUVIMED